GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bone Biologics
Bone Biologics develops protein-based bone implants. Its stock price is a venture bet on the success of its technology in spinal surgery. The stock price reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Specialized medical equipment
Bone Biologics is an orthopedic company developing protein-based bone grafts to stimulate bone growth during spinal surgeries. We've categorized it as "Specialized Medical Equipment." The chart below shows the dynamics of the regenerative medicine sector.
Broad Market Index - GURU.Markets
Bone Biologics is a biotech company developing bone regeneration drugs used in orthopedics and spinal surgery. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
BBLG - Daily change in the company's share price Bone Biologics
For Bone Biologics Corporation, which operates in orthopedics, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing the risks of its bone regeneration platform.
Daily change in the price of a set of shares in a market segment - Specialized medical equipment
Bone Biologics develops orthobiological products for bone tissue regeneration using the NELL-1 protein. This is an innovative but risky area of medical technology. The chart below shows the volatility in the specialized medical equipment sector, providing context for BBLG stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
Bone Biologics develops protein-based bone implants for spinal surgery. This innovative medtech company's shares are responding to clinical successes and regulatory decisions. Its history reflects the medtech sector's contribution to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bone Biologics
Bone Biologics Corporation's year-over-year performance is a story about the development of its bone regeneration product. Its 12-month market cap depends entirely on progress in clinical trials. The success of its protein drug could offer orthopedic surgeons a safer and more effective alternative to existing methods.
Annual dynamics of market capitalization of the market segment - Specialized medical equipment
Bone Biologics is an early-stage biotech company developing bone regeneration products. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the high risks and speculative nature typical of this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bone Biologics, a regenerative orthopedics company, is a medical technology startup whose growth hinges on the success of clinical trials. Its performance relative to the market reflects investors' assessment of the potential of its bone restoration technology. It's a long and risky road to commercialization.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bone Biologics
Bone Biologics is an orthopedic company developing bone implants. Being in the development stage, its monthly valuation is dependent on news. Progress in preclinical and clinical trials is the main event shaping investor expectations.
Monthly dynamics of market capitalization of the market segment - Specialized medical equipment
The regenerative medicine sector for bone tissue restoration is a promising, albeit early, area of biotechnology. Its market capitalization dynamics, shown in the chart, reflect the speculative interest in new surgical methods. Bone Biologics is a company active in this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bone Biologics, a company developing bone regeneration drugs, is a high-risk biotech. Its shares move solely on news of clinical trials, completely ignoring overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bone Biologics
Bone Biologics, a company developing a bone tissue regeneration product, operates at the intersection of biotechnology and orthopedics. Its weekly stock price is reflecting clinical trial data demonstrating the effectiveness of its platform in complex surgical procedures.
Weekly dynamics of market capitalization of the market segment - Specialized medical equipment
Bone Biologics is developing a protein-based bone graft that stimulates bone growth during spinal surgeries. This technology holds promise in orthopedics. The chart below shows how investors are reacting to clinical trial news compared to other companies in the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bone Biologics is developing a bone graft, a promising technology for orthopedics. The chart below shows how investors are reacting to news of clinical trials compared to other companies in the sector and the broader market.
Market capitalization of the company, segment and market as a whole
BBLG - Market capitalization of the company Bone Biologics
Bone Biologics' market capitalization chart reflects investor sentiment toward its bone regeneration product. Its dynamics reflect the market's confidence in its NELL-1 peptide for use in spinal surgery. Its extremely low valuation demonstrates both the company's enormous potential market and the very high risk associated with its preclinical development stage.
BBLG - Share of the company's market capitalization Bone Biologics within the market segment - Specialized medical equipment
Bone Biologics is an orthopedic company developing a bone graft based on the NELL-1 protein. Its market share in the regenerative medicine sector is negligible, but it is based on promising science. Its capitalization is a bet on its product, which could improve and accelerate bone fusion during spinal surgeries.
Market capitalization of the market segment - Specialized medical equipment
This graph shows the total value of the entire specialized medical equipment sector. For Bone Biologics, with its bone regeneration technology, this line is a map of the future of orthopedics. The rising graph reflects how biotechnology is penetrating surgery, promising to improve and accelerate bone healing after injuries and surgeries.
Market capitalization of all companies included in a broad market index - GURU.Markets
Bone Biologics develops protein-based bone grafts for use in spinal surgery. Its market capitalization is based on the value of regenerative medicine in orthopedics. This represents the overall market share of the bone regeneration business.
Book value capitalization of the company, segment and market as a whole
BBLG - Book value capitalization of the company Bone Biologics
Bone Biologics is developing bone grafts based on the NELL-1 protein. Its book value is its intellectual property and financial resources. This is its capital for preclinical and clinical trials. How has this regenerative capital changed? The chart below shows.
BBLG - Share of the company's book capitalization Bone Biologics within the market segment - Specialized medical equipment
Bone Biologics Corporation develops products for bone tissue regeneration. Its technology, based on the NELL-1 protein, requires resources: laboratories for research and manufacturing facilities for implant production. The chart shows its share of the R&D infrastructure for orthopedic regenerative medicine.
Market segment balance sheet capitalization - Specialized medical equipment
Bone Biologics is a medical technology company. This sector, as the chart shows, is capital-intensive. Bone Biologics is developing a unique implant, and its capital is invested in R&D and preparation for manufacturing this complex product.
Book value of all companies included in the broad market index - GURU.Markets
Bone Biologics' assets are not implants, but a scientific platform for developing a bone graft based on the NELL-1 protein, which stimulates bone growth. The book value reflects capital invested in preclinical and clinical research of this regenerative product.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bone Biologics
Bone Biologics is an orthopedic company developing a bone regeneration product. Its market value is determined by its technology and its potential to offer a new alternative for complex spinal surgeries.
Market to book capitalization ratio in a market segment - Specialized medical equipment
Bone Biologics is a company developing a bone tissue regeneration product. Its high valuation on this chart reflects investors' faith in its technology and its potential for application in orthopedics and spinal surgery, where the need for such products is high.
Market to book capitalization ratio for the market as a whole
Bone Biologics develops products for bone tissue regeneration, a niche area in orthopedics. The company's market value reflects the potential of its technology to improve surgical outcomes. This chart helps assess investor sentiment for highly specialized medical technologies.
Debts of the company, segment and market as a whole
BBLG - Company debts Bone Biologics
Bone Biologics, a company developing bone tissue regeneration drugs, is in the preclinical stage and is entirely dependent on seed funding to finance its research. This graph reflects the initial, riskiest phase of developing a new medical product.
Market segment debts - Specialized medical equipment
Bone Biologics is a biotech company developing a protein-based product to stimulate bone growth, which could be used in spinal surgeries. This chart shows how the company is funding its preclinical and clinical trials in the development stage, aiming to enter the large orthopedic implant market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bone Biologics
Bone Biologics develops orthobiological products to stimulate bone growth based on the NELL-1 protein. Bringing such innovative implants to market is a lengthy and expensive process, requiring extensive clinical trials. This chart shows how the company leverages its high-risk developments.
Market segment debt to market segment book capitalization - Specialized medical equipment
Bone Biologics is developing a protein-based product for bone tissue regeneration, which could be used in spinal surgery. This chart shows how the company is funding its long-term clinical trials. It compares its debt load to the market capitalization of the entire medical devices and biotech sector.
Debt to book value of all companies in the market
Bone Biologics is developing a protein-based bone graft that could promote bone regeneration. Orthopedic innovations require lengthy clinical trials and investment. How heavily does the company rely on debt? This chart of total market debt helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Bone Biologics
Bone Biologics is a medical technology company developing a bone graft based on the NELL-1 protein to stimulate bone growth. This chart shows how investors value the company in the field of orthopedic regenerative medicine. The valuation is heavily dependent on the results of clinical trials.
P/E of the market segment - Specialized medical equipment
Bone Biologics Corporation is a medical technology company focused on developing bone grafts based on the NELL-1 protein to stimulate bone growth during spinal surgeries. This chart illustrates the average valuation in the specialized medical device sector, which values innovative regenerative technologies.
P/E of the market as a whole
Bone Biologics Corporation is a medical technology company focused on developing bone regeneration drugs based on the NELL-1 protein for use in spinal surgery. This chart reflects investors' overall risk appetite. It helps understand whether BBLG's high valuation is based on faith in its unique technology or whether it is moving in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bone Biologics
Bone Biologics is an orthopedic company developing a bone graft based on the NELL-1 protein to stimulate bone growth. The company's future depends on the success of this product in clinical trials. This chart reflects investor expectations regarding the commercial potential of this regenerative technology in spine surgery.
%20P%2FE%20Bone%20Biologics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bone-Biologics&v=1772513590639 "Chart of the company's future (projected) P/E Bone Biologics")
Future (projected) P/E of the market segment - Specialized medical equipment
Bone Biologics is developing a bone graft based on the NELL-1 protein for use in spinal surgery. The goal is to offer a safer alternative to existing products. The chart shows average profitability expectations in the sector, helping to understand the level of investor confidence in this regenerative technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-medical-equipment&v=1772513590643 "Future (projected) P/E graph of the market segment - Specialized medical equipment")
Future (projected) P/E of the market as a whole
Bone Biologics is developing a protein-based bone graft that stimulates bone growth and can be used in spinal surgery. This chart of overall medtech sentiment reflects investor confidence in the potential of regenerative medicine to improve surgical outcomes.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513590646 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bone Biologics
Bone Biologics is a biotech company developing a protein drug to stimulate bone growth during spinal surgery. The company is currently in clinical trials. This chart shows the investment in developing a product that could become an alternative to traditional bone grafting methods.
Profit of companies in the market segment - Specialized medical equipment
Bone Biologics Corp. is a medical technology company developing a protein-based bone graft that stimulates bone growth and can be used in spine surgeries. This chart shows overall profitability in the specialized medical device sector, where regenerative medicine offers new opportunities for surgery.
Overall market profit
Bone Biologics Corporation develops bone tissue regeneration products. The company is currently in clinical trials. Its future depends on the success of these studies and regulatory approval. The demand for such products in orthopedics and dentistry is not dependent on economic conditions, but rather is determined by medical indications.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bone Biologics
Bone Biologics is developing a protein-based bone graft designed to stimulate bone growth during spine surgeries. Future revenue depends on the success of clinical trials and FDA approval. This chart reflects analysts' speculative expectations for its product in orthopedic surgery.
%20profit%20of%20the%20company%20Bone%20Biologics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bone-Biologics&v=1772513590671 "Graph of future (projected) profit of the company Bone Biologics")
Future (predicted) profit of companies in the market segment - Specialized medical equipment
Bone Biologics is developing a bone graft based on the NELL-1 protein to stimulate bone growth during spinal surgeries. This technology could become an alternative to existing methods. The company's success depends on clinical trials. This chart shows profitability expectations for the specialized medical equipment sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-medical-equipment&v=1772513590688 "Graph of future (predicted) profits of companies in a market segment - Specialized medical equipment")
Future (predicted) profit of the market as a whole
Bone Biologics is an orthopedic company developing bone regeneration products. Its success depends on obtaining approvals and the acceptance of its technology by surgeons. This economic outlook impacts healthcare system budgets and their willingness to implement innovative, but potentially expensive, products.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513590696 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bone Biologics
Bone Biologics is developing a protein-based bone graft for use in spinal surgery. There is no revenue in clinical trials. This chart reflects investor sentiment regarding the product and its potential to become a new standard in orthopedic surgery.
P/S market segment - Specialized medical equipment
Bone Biologics is a biotech company developing a bone regeneration product for use in spinal surgery. Their technology is based on a protein that stimulates bone growth, offering an alternative to traditional methods. This chart shows the average revenue estimate for the sector, helping to assess the potential of this regenerative technology.
P/S of the market as a whole
Bone Biologics is a biotech company developing a bone regeneration product for use in spinal surgery. This chart emphasizes that the valuation of such companies is based on their product's potential to improve the outcomes of complex surgeries, not on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bone Biologics
Bone Biologics is an orthopedic company developing a protein-based bone graft that stimulates bone growth. Its revenue valuation is crucial for the company. It reflects investors' expectations for the success of its product in clinical trials and its potential to become an effective alternative to existing methods in spine surgery and other areas.
%20P%2FS%20Bone%20Biologics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bone-Biologics&v=1772513590711 "The graph of the company's future (projected) P/S Bone Biologics")
Future (projected) P/S of the market segment - Specialized medical equipment
Bone Biologics is a biotech company developing a bone regeneration product for use in spinal surgery. This chart compares the company's estimated future sales with expectations for the medical device sector. It shows whether investors believe its protein drug will be an effective alternative to traditional bone grafting methods.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-medical-equipment&v=1772513590715 "Future (projected) P/S market segment graph - Specialized medical equipment")
Future (projected) P/S of the market as a whole
Bone Biologics is developing a bone graft based on the NELL-1 protein to stimulate bone growth during spinal surgeries. The company's future depends on the success of this product in clinical trials. This chart of overall market expectations reflects investor confidence that regenerative medicine can offer better solutions for orthopedics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513590734 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bone Biologics
This chart shows the financial performance of Bone Biologics, a company developing a protein-based bone graft to stimulate bone growth during spinal surgeries. Being in clinical development, the company has no commercial revenue.
Sales of companies in the market segment - Specialized medical equipment
Bone Biologics Corporation is a biotechnology company focused on developing a bone tissue regeneration product based on the NELL-1 protein. Being in the development stage, it does not yet have revenue. Its future revenue will depend on the success of this technology in orthopedic and spinal surgery.
Overall market sales
Bone Biologics Corporation develops bone regenerative products based on the NELL-1 protein, designed to improve bone healing. The company operates in the cutting-edge field of orthopedics. This overall economics schedule does not affect the company's prospects, which depend on the results of clinical trials and the acceptance of its technology by surgeons.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bone Biologics
Bone Biologics is a medical technology company developing a bone graft based on the NELL-1 protein to stimulate bone growth during spinal surgeries. Future revenue is dependent on the success of clinical trials. This chart reflects analyst expectations for potential demand for its innovative product in orthopedics and spinal surgery.
%20sales%20of%20the%20company%20Bone%20Biologics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bone-Biologics&v=1772513590831 "Schedule of future (projected) sales of the company Bone Biologics")
Future (projected) sales of companies in the market segment - Specialized medical equipment
Bone Biologics Corporation is developing protein-based bone grafts for use in spinal surgery. This chart illustrates the forecast for the orthopedic equipment market. Is demand for biological materials that promote bone regeneration growing? This illustrates the overall trend in this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-medical-equipment&v=1772513590842 "Schedule of future (projected) sales of companies in the market segment - Specialized medical equipment")
Future (projected) sales of the market as a whole
Bone Biologics is an orthopedic company developing products for bone regeneration. Demand for its products will depend on the number of orthopedic surgeries and the acceptance of its technology by surgeons. This overall economic activity curve may indirectly influence the number of elective surgeries, but the primary driver is clinical need.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513590850 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bone Biologics
Bone Biologics is a biomedical company developing a protein-based product to stimulate bone growth during spinal surgery. This chart reflects its financial performance during the preclinical and clinical development stages. Profitability is a future goal and will depend on the success of its platform as an alternative to traditional bone grafting methods.
Market segment marginality - Specialized medical equipment
Bone Biologics Corporation is a medical technology company developing a protein-based bone graft to stimulate bone growth. This chart reflects its financial position at the clinical development stage, where profitability depends on successful trials and regulatory approval for use in spinal surgery.
Market marginality as a whole
Bone Biologics, as its name suggests, develops products for bone tissue regeneration. Its success depends on the results of clinical trials and the acceptance of its technology by surgeons. This overall profitability chart reflects the state of the medical device sector and the healthcare system's readiness to implement innovative orthopedic solutions.
Employees in the company, segment and market as a whole
Number of employees in the company Bone Biologics
Bone Biologics is a biotech company developing a protein-based product for bone regeneration after spinal surgery. Its very small staff consists of key managers and scientists who manage research. This graph shows the compact team working to advance the product through complex regulatory processes.
Share of the company's employees Bone Biologics within the market segment - Specialized medical equipment
Bone Biologics is an orthopedic company developing a protein-based product to stimulate bone growth during spinal surgeries. Its activities are focused on R&D and clinical trials. This graph shows the company's market share, reflecting its scientific focus and the stage of development of its regenerative product.
Number of employees in the market segment - Specialized medical equipment
Bone Biologics is an orthopedic company developing a bone graft based on the NELL-1 protein to stimulate bone growth. The chart shows employment in the specialized medical equipment sector. This technology could improve outcomes in spinal surgeries and other bone procedures by accelerating fusion.
Number of employees in the market as a whole
Bone Biologics is developing a protein-based product for bone tissue regeneration, which could be used in spinal surgery. The company's growth depends on success in clinical trials. Given the overall dynamics in this chart, it exemplifies a highly specialized biotech company working to create breakthrough medical products.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bone Biologics (BBLG)
Bone Biologics is a biotech company developing a platform (based on the NELL-1 protein) for bone tissue regeneration. This is an early-stage R&D company. This chart shows how the market values their IP. It reflects the speculative market value per scientist, which is a bet on their technology in orthopedics.
%20of%20the%20company%20Bone%20Biologics%20(BBLG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bone-Biologics-BBLG&v=1772513590914 "Chart of market capitalization per employee (in thousands of dollars) of the company Bone Biologics (BBLG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Bone Biologics (BBLG) develops orthobiological products to stimulate bone growth during spine surgeries. In this medical niche, this figure reflects the potential of their key product, NELL-1. The high market capitalization per employee suggests that their technology could become a safer and more effective alternative to existing bone grafts.
%20by%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-medical-equipment&v=1772513590923 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Bone Biologics is developing a protein-based bone graft for use in spinal surgery. The company's valuation is based on the potential of this regenerative medicine technology. The chart shows a high valuation per employee, as a successful product could become a significant alternative to existing methods and fill a significant niche.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513590926 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bone Biologics (BBLG)
Bone Biologics is a clinical-stage biotech company developing a bone tissue regeneration product (for spinal surgery). This graph shows the net loss per employee. It reflects that every scientist at the company represents an R&D investment, funded for expensive clinical trials.
%20Chart%20Bone%20Biologics%20(BBLG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bone-Biologics-BBLG&v=1772513590929 "Company Profit Per Employee (in thousands of dollars) Chart Bone Biologics (BBLG)")
Profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Bone Biologics Corporation develops bone tissue regeneration products based on the NELL-1 protein. In orthopedic biotechnology, efficiency per employee reflects the potential of their unique platform. The graph shows the financial return per team, allowing one to assess progress toward commercialization of this new approach to bone treatment.
%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-medical-equipment&v=1772513590931 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Bone Biologics is a biotech company focused on bone regeneration. They are developing a product (based on the NELL-1 protein) for use in spinal surgery. This is an R&D business. This graph, showing average market efficiency, helps to understand the contrast with R&D businesses, where capital is invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513590932 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bone Biologics (BBLG)
Bone Biologics is developing bone tissue regeneration products based on the NELL-1 protein. There is no revenue per employee during the R&D phase. This schedule is important as a sign of the future: a successful product that accelerates bone fusion will be in demand in surgery and could generate significant revenue for a small research team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bone-Biologics-BBLG&v=1772513590934 "Sales chart per company employee Bone Biologics (BBLG)")
Sales per employee in the market segment - Specialized medical equipment
Bone Biologics (BBLG) is a clinical-stage biotech developing a protein drug (NELL-1) to stimulate bone growth, primarily for spinal surgery (vertebral fusion). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of BBLG's R&D staffing efficiency.
Sales per employee for the market as a whole
Bone Biologics (BBLG) is a biotech company developing a bone regeneration product for use in spinal surgeries. Currently, their focus is on R&D. This chart reflects their clinical stage: the company is investing in research.
Short shares by company, segment and market as a whole
Shares shorted by company Bone Biologics (BBLG)
Bone Biologics (BBLG) is developing a bone regeneration product intended to aid in spinal surgeries. This chart tracks short positions. Short positions reflect a bet that this complex biotech product will fail to prove its effectiveness in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bone-Biologics-BBLG&v=1772513590954 "Short Shares Chart for the Company Bone Biologics (BBLG)")
Shares shorted by market segment - Specialized medical equipment
Bone Biologics (BBLG) develops orthobiologic drugs (based on the NELL-1 protein) to stimulate bone growth, particularly during spine surgeries. This chart shows the overall short position in the specialized medical equipment sector, highlighting investor concerns about the risks of clinical trials.
Shares shorted by the overall market
Bone Biologics is developing a protein therapy for bone regeneration, targeting the spinal surgery market. It's a speculative medtech. This chart illustrates the general fear. When investors are afraid, they don't want to wait for long FDA approvals. They sell off BBLG shares, fearing the company won't have enough cash to complete trials in a market downturn.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bone Biologics (BBLG)
This chart shows investor confidence in Bone Biologics' technology. The company is developing a protein implant (NELL-1) for bone fusion during spinal surgery. It's a risky bet. "Overheating" (above 70) occurs with positive preclinical data or the start of human trials. Any delays or doubts about the effectiveness of this complex technology lead to "overselling."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bone-Biologics-BBLG&v=1772513590960 "RSI 14 indicator chart for the company's stock Bone Biologics (BBLG)")
RSI 14 Market Segment - Specialized medical equipment
Bone Biologics is a preclinical biotech company developing a protein-based product (NELL-1) designed to stimulate bone tissue regeneration during spinal surgery. This chart measures the overall momentum in the specialized medical device sector and helps assess how the market views this industry.
RSI 14 for the overall market
Bone Biologics focuses on regenerative medicine for bones, which requires lengthy and expensive research. Funding for such developments is highly dependent on investors' overall risk appetite. This chart measures the market's "temperature." When the market is "overheated" (euphoria), investors are more willing to invest in promising biotechs. During panic (oversold conditions), BBLG's access to capital sharply decreases.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BBLG (Bone Biologics)
Bone Biologics is a biotech company developing a protein drug (NELL-1) for bone regeneration, intended for use in spinal surgery. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BBLG-Bone-Biologics&v=1772513590966 "A chart showing analyst consensus forecasts for the expected stock price. BBLG (Bone Biologics)")
The difference between the consensus estimate and the actual stock price BBLG (Bone Biologics)
Bone Biologics is a biotech company developing a protein implant (NELL-1) designed to stimulate bone regeneration during spinal surgery. This chart measures the gap between the current stock price and the consensus target price. It shows whether experts believe in this bone-fusion technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BBLG-Bone-Biologics&v=1772513590968 "A chart showing the difference between the consensus forecast and the actual stock price. BBLG (Bone Biologics)")
Analyst consensus forecast for stock prices by market segment - Specialized medical equipment
Bone Biologics is a single-molecule R&D biotech company. The company is developing a protein drug (NELL-1) for vertebral fusion during spinal surgery. This chart reflects analysts' overall expectations for the specialized medical equipment sector. It shows whether experts believe a breakthrough in bone regeneration is possible.
Analysts' consensus forecast for the overall market share price
Bone Biologics is a biotech company developing protein-based implants for bone regeneration, primarily for spinal surgery. This chart shows the overall market "risk appetite." For BBLG, a clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bone Biologics
Bone Biologics is a bone biotech company. Their signature product is NELL-1, a protein (an R&D product) that (according to them) stimulates bone growth (rather than simply cementing it), which they are trying to use in spine surgery. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Specialized medical equipment
Bone Biologics is a company aiming to transform spinal surgery. They are developing a protein drug (NELL-1) to stimulate bone growth, which could replace traditional grafts. This chart compares their composite index to the sector, showing how this regenerative approach compares to other hardware manufacturers.
The AKIM Index for the overall market
Bone Biologics is a company developing a protein (rhNELL-1) for bone tissue regeneration (fusion). This chart, reflecting the market average, is a backdrop. It helps assess how BBLG, an orthopedic biotech company, compares to overall macroeconomic trends in medicine.
